A Study of ATB1651 in Adults With Mild to Moderate Onychomycosis

NCT05089409 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Onychomycosis

Interventions

DRUG: ATB1651, 2 mg/mL
DRUG: ATB1651, 5 mg/mL
DRUG: ATB1651, 10 mg/mL
DRUG: ATB1651, 20 mg/mL
DRUG: ATB1651, 30 mg/mL
OTHER: Placebo

Sponsor

AmtixBio Co., Ltd.

Collaborators

[object Object]